Latest Publications

Latest Publications

Eyam Vaccines and Immunotherapeutics Welcomes New Board Members and Scientific Advisors

By |2022-01-10T21:42:05+00:00January 10th, 2022|Latest Publications|

Eyam Vaccine and Immunotherapeutics (EYAM), a next-generation vaccine biotechnology company, announced today an agreement with Veristat, a scientific-minded, global clinical research organization (CRO), to plan and coordinate clinical trials of their vaccine program against SARS-CoV-2. 

Comments Off on Eyam Vaccines and Immunotherapeutics Welcomes New Board Members and Scientific Advisors

MYND Life Sciences Announces LOI with Eyam Vaccines and Immunotherapeutics

By |2021-09-03T18:28:10+00:00June 17th, 2021|Latest Publications|

MYND Life Sciences Inc. (CSE: MYND) (“MYND“) a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce a Letter of Intent (“LOI”) with Eyam Vaccines and Immunotherapeutics (“Eyam“).

Comments Off on MYND Life Sciences Announces LOI with Eyam Vaccines and Immunotherapeutics

B.C.’s ‘world-class’ biotech sector plays key role in developing COVID-19 treatments and vaccines

By |2021-09-03T19:20:03+00:00May 10th, 2021|Latest Publications|

B.C.’s ‘world-class’ biotech sector plays key role in developing COVID-19 treatments and vaccines May [...]

Comments Off on B.C.’s ‘world-class’ biotech sector plays key role in developing COVID-19 treatments and vaccines

Preclinical Testing of Next-Generation COVID-19 Vaccine Candidates targeting SARS-CoV-2 Variants

By |2021-09-03T20:20:25+00:00April 15th, 2021|Latest Publications|

Eyam Vaccines and Immunotherapeutics (EYAM) today announced that Dr. James LaBelle, Chief Medical Officer of Ripplenami, joined EYAM’s board of directors.

Comments Off on Preclinical Testing of Next-Generation COVID-19 Vaccine Candidates targeting SARS-CoV-2 Variants

Bioinformatics Scientist, Dr. Paolo Ribeca, Joins Eyam Vaccines and Immunotherapeutics’ Scientific Advisory Board 

By |2021-01-27T21:45:28+00:00January 27th, 2021|Latest Publications|

Eyam Vaccines and Immunotherapeutics (EYAM) today announced that Dr. James LaBelle, Chief Medical Officer of Ripplenami, joined EYAM’s board of directors.

Comments Off on Bioinformatics Scientist, Dr. Paolo Ribeca, Joins Eyam Vaccines and Immunotherapeutics’ Scientific Advisory Board 

Dr. James LaBelle, former Chief Medical Officer of Scripps Health, Joins Eyam Vaccines and Immunotherapeutics Board of Directors

By |2021-01-13T21:18:13+00:00January 13th, 2021|Latest Publications|

Eyam Vaccines and Immunotherapeutics (EYAM) today announced that Dr. James LaBelle, Chief Medical Officer of Ripplenami, joined EYAM’s board of directors.

Comments Off on Dr. James LaBelle, former Chief Medical Officer of Scripps Health, Joins Eyam Vaccines and Immunotherapeutics Board of Directors
Go to Top